SGHT

Sight Sciences is a cautious 'buy,' as recent reimbursement wins and product momentum support a positive outlook, offset by liquidity pressures and ongoing reimbursement and utilization challenges. SGHT's OMNI Ultra Surgical System launch and updated TearCare label provide incremental adoption tailwinds, but procedure costs/reimbursement and surgeon preference remain key hurdles. Q2 revenue grew 20% with strong dry eye business acceleration, improved gross margins, and reduced cash burn; Aetna coverage adds 25 million insured lives to the glaucoma business.

MENLO PARK, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform eye care and improve patients' lives, today announced the commercial availability of the OMNI® Ultra Surgical System (OMNI Ultra), an expansion of its pioneering ab interno canaloplasty platform. The new technology will be featured at this year's American Academy of Ophthalmology (AAO) annual meeting held on October 9-12 in New Orleans, Louisiana.

Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

MENLO PARK, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.

MENLO PARK, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies intended to transform care and improve patients' lives, today announced that, effective August 18, 2026, the U.S. Food and Drug Administration (FDA) updated the TearCare® System (TearCare) Indications for Use to state:

Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript

Sight Sciences NASDAQ: SGHT reported second-quarter revenue growth of 20% year over year, supported by gains in its interventional glaucoma and interventional dry eye businesses, while reducing operating expenses and cash usage. The company raised its full-year revenue outlook and lowered its adjusted operating expense guidance.

Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform eyecare and improve patients' lives, today announced that Aetna, Inc.'s (Aetna) updated Glaucoma Surgery Policy for its commercial plans now recognizes the OMNI® Surgical System (OMNI) and the SION® Surgical Instrument (SION) as medically necessary for the treatment of mild-to-moderate open-angle glaucoma when specified clinical criteria are met, establishing coverage of Sight Sciences' interventional glaucoma technologies.

New system expands the Company's leadership in interventional glaucoma with the first FDA cleared MIGS device for single pass canaloplasty with TruSync™ Plus innovation. New system expands the Company's leadership in interventional glaucoma with the first FDA cleared MIGS device for single pass canaloplasty with TruSync™ Plus innovation.